INAF Stock Overview
PT Indofarma Tbk, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
PT Indofarma Tbk Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Rp356.00 |
52 Week High | Rp730.00 |
52 Week Low | Rp356.00 |
Beta | -0.024 |
1 Month Change | -8.72% |
3 Month Change | -41.16% |
1 Year Change | -49.14% |
3 Year Change | -85.53% |
5 Year Change | -91.87% |
Change since IPO | 73.66% |
Recent News & Updates
Recent updates
Shareholder Returns
INAF | ID Pharmaceuticals | ID Market | |
---|---|---|---|
7D | -9.6% | 5.9% | 0.8% |
1Y | -49.1% | -23.2% | 9.1% |
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -23.2% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 9.1% over the past year.
Price Volatility
INAF volatility | |
---|---|
INAF Average Weekly Movement | 6.9% |
Pharmaceuticals Industry Average Movement | 3.6% |
Market Average Movement | 4.7% |
10% most volatile stocks in ID Market | 11.6% |
10% least volatile stocks in ID Market | 2.2% |
Stable Share Price: INAF's share price has been volatile over the past 3 months.
Volatility Over Time: INAF's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1918 | 1,086 | - Yeliandriani | https://indofarma.id |
PT Indofarma Tbk, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. It offers laboratory, pharmaceutical, and health equipment; orthopedic and prosthetic equipment; industrial machinery for packaging, bottling, and canning; provides health consultancy services; and trades in laboratory equipment, pharmacy, and medicines. The company serves medicine product, medical and dental equipment, electromedical and electrotherapy equipment, herbal processing, and tea processing industries, as well as furniture industry for operations, medical care, and dental care.
PT Indofarma Tbk Fundamentals Summary
INAF fundamental statistics | |
---|---|
Market cap | Rp1.10t |
Earnings (TTM) | -Rp437.05b |
Revenue (TTM) | Rp684.91b |
1.6x
P/S Ratio-2.5x
P/E RatioIs INAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INAF income statement (TTM) | |
---|---|
Revenue | Rp684.91b |
Cost of Revenue | Rp867.00b |
Gross Profit | -Rp182.08b |
Other Expenses | Rp254.97b |
Earnings | -Rp437.05b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -141.02 |
Gross Margin | -26.58% |
Net Profit Margin | -63.81% |
Debt/Equity Ratio | -728.4% |
How did INAF perform over the long term?
See historical performance and comparison